Investors / Media
View our Corporate Presentation
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference
NRx Pharmaceuticals, Inc. today announced its Chief Executive Officer, Stephen Willard, and other executive leaders will be presenting an update to the company’s business at the H.C. Wainwright & Co. 24th Annual Global Investment Conference.
Relief Therapeutics Holding SA And NRx Pharmaceuticals, Inc. Announce Tentative Settlement Of Pending Litigation
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. today announced that they have agreed to a tentative settlement of their pending litigation. The parties have agreed to work collaboratively to finalize the settlement within the next 30 days.
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference
NRx Pharmaceuticals, Inc. today announced its Chief Executive Officer, Stephen Willard, and other executive leaders will be presenting an update to the company’s business at the H.C. Wainwright & Co. 24th Annual Global Investment Conference.
Relief Therapeutics Holding SA And NRx Pharmaceuticals, Inc. Announce Tentative Settlement Of Pending Litigation
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. today announced that they have agreed to a tentative settlement of their pending litigation. The parties have agreed to work collaboratively to finalize the settlement within the next 30 days.
NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise
NRx Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2022 and provided a business and clinical update.
NRx Pharmaceuticals to Report Second Quarter 2022 Results on August 15, 2022
NRx Pharmaceuticals, Inc. today announced that management will report second quarter 2022 financial results prior to the market open on August 15, 2022.
CEO Update on Recent Findings Related to Serotonin and its Role in Depression
In light of recent findings related to serotonin and its role in depression, investors have asked us to provide more specific information on the primary target addressed by D-cycloserine, a component of NRX-101.
Scientific Update from NRx Pharmaceuticals Chief Scientist, Jonathan Javitt, MD, MPH
In light of recent findings related to serotonin and its role in depression, investors have asked us to provide more specific information on the primary target addressed by D-cycloserine, a component of NRX-101.
Investor Relations
Tags
NRx Press Archives
Cantor Neurology & Psychiatry Conference
October 6-7, 2022
Ritz Carlton Hotel
San Francisco, CA
